
News|Videos|February 6, 2021
Researchers Say CAEL-101 is an Effective Amyloid Light Chain Amyloidosis Treatment
Pharmacy Times interviewed Jason Valent, MD, of the Cleveland Clinic about his new research surrounding CAEL-101, a treatment for patients living with amyloid light chain amyloidosis.
Advertisement
Pharmacy Times® interviewed Jason Valent, MD, of the Cleveland Clinic about his new research surrounding CAEL-101, a treatment for patients living with amyloid light chain amyloidosis, which was presented at the 62nd American Society of Hematology Annual Meeting & Exposition.
The full conversation can be found in the video above.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Approves First-in-Class Daraxonrasib for Metastatic Pancreatic Cancer
2
What Pharmacists Should Know About Novo Nordisk-Eli Lilly GLP-1 Ad Suit
3
FDA Approves Dolutegravir for HIV Treatment in Newborns
4
FDA Grants Fast Track Designation to CK0803 for Amyotrophic Lateral Sclerosis
5


































































































